CHRNA4 and cancer: Results were grouped based on distinct cancer types (breast, lung, prostate) and specific nAChR subtypes (e.g., α7, α9, α5), aligning them with their relevant key signaling pathways (e.g., EGFR/ERK1/2, PI3K/AKT, MAPK), and summarizing their contributions to cancer progression.